肺癌免疫检查点抑制剂耐药的管理:治疗与新型策略
部分肺癌患者可从免疫检查点抑制剂(ICI)获得长期临床获益,但多数患者会在治疗中或停药后出现疾病进展。免疫耐药的定义因临床和生物学特征而异,按既往缓解模式和发生时机分为原发性与获得性耐药,与肿瘤内在和外在机制相关。本综述回顾了ICI耐药机制、临床定义、管理及在研新型策略的证据。
要点
- 免疫耐药按既往缓解模式和发生时机分为原发性和获得性耐药。
- 耐药机制涉及肿瘤内在和外在机制,临床耐药模式决定不同处理策略。
- 多种联合策略在研以延迟或预防ICI耐药,包括阻断共抑制信号、激活共刺激信号、调节肿瘤微环境和靶向T细胞致敏。
核心结论
- 本综述回顾了肺癌ICI耐药的机制、临床定义和管理证据,以及在此背景下正在研究的新型策略。
研究设计与样本
- 本综述回顾了关于肺癌免疫耐药机制、临床定义和ICI耐药管理的现有证据,以及在此背景下正在研究的新型策略数据。
主要发现
- 部分肺癌患者可从ICI获得长期临床获益,但多数患者会在治疗中或停药后出现疾病进展。
- 免疫耐药的定义因不同临床和生物学特征而异,原发性耐药和获得性耐药按既往缓解模式和发生时机识别,与肿瘤内在和外在机制相关。
- 临床耐药模式决定不同的临床处理方法。
- 目前有多种联合疗法在研以延迟或预防ICI耐药,包括阻断免疫共抑制信号、激活共刺激功能、调节肿瘤微环境和靶向T细胞致敏。
关键数值与推荐
- 按既往缓解模式和发生时机识别原发性耐药和获得性耐药。
临床怎么用
- 临床耐药模式决定不同的临床处理方法。
- 根据特定生物学耐药机制定制治疗被认为是改善临床试验设计和结果的理想方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoint inhibitors (ICIs). However, most patients develop disease progression during treatment or after treatment discontinuation. Definitions of immune resistance are heterogeneous according to different clinical and biologic features. Primary resistance and acquired resistance, related to tumor-intrinsic and tumor-extrinsic mechanisms, are identified according to previous response patterns and timing of occurrence. The clinical resistance patterns determine differential clinical approaches. To date, several combination therapies are under development to delay or prevent the occurrence of resistance to ICIs, including the blockade of immune coinhibitory signals, the activation of those with costimulatory functions, the modulation of the tumor microenvironment, and the targeting T-cell priming. Tailoring the specific treatments with distinctive biologic resistance mechanisms would be ideal to improve the design and results of clinical trial. In this review, we reviewed the available evidence on immune resistance mechanisms, clinical definitions, and management of resistance to ICIs in lung cancer. We also reviewed data on novel strategies under investigation in this setting.
引用
- Passaro A, Brahmer J, Antonia S, et al. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022. PMID: 34985992. doi:10.1200/JCO.21.01845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。